Intellia Therapeutics (NTLA) Other Working Capital Changes (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Other Working Capital Changes for 12 consecutive years, with -$6.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Working Capital Changes fell 30.72% year-over-year to -$6.7 million; the TTM figure through Mar 2026 stood at -$29.7 million (down 36.11% YoY), while the FY2025 annual figure was -$28.1 million, down 27.34% from the prior year.
• Other Working Capital Changes improved to -$6.7 million in Q1 2026 per NTLA's latest filing, from -$14.0 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $23.0 million in Q3 2025 and bottomed at -$19.2 million in Q2 2025.
• Historically, Other Working Capital Changes has averaged $2.4 million across 5 years, with a median of $1.2 million in 2022.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes sank 186.55% — and 2023, when it jumped 308.83%.
• Intellia Therapeutics' Other Working Capital Changes stood at -$16.7 million in 2022, then surged by 308.83% to $34.9 million in 2023, then plunged by 116.73% to -$5.8 million in 2024, then slumped by 139.18% to -$14.0 million in 2025, then jumped by 52.36% to -$6.7 million in 2026.
• Business Quant data shows NTLA's Other Working Capital Changes at -$6.7 million in Q1 2026, -$14.0 million in Q4 2025, and -$4.9 million in Q3 2025.